Key Highlights

  • Firebrick decided on 29 September 2026 to enter the US retail pharmacy market with its Nasodine products, led by US commercial director Al Moghaddam.
  • Nasodine Sinus Rinse launched on 21 October 2026, after the end of the quarter.
  • Cash was A$875,000 at quarter end, with net operating cash outflow of A$398,000 and an estimated runway of 2.2 quarters.

Firebrick Pharma Limited (ASX:FRE) reported for the September 2026 quarter that it decided on 29 September 2026 to enter the US retail pharmacy market with its Nasodine products. The company cited growth in online sales and its attendance at the NACDS retail trade expo in Boston in August. The report, released on 23 October 2026, also confirmed a further product launch and set out the company's cash position.

To lead the effort, Mr Al Moghaddam, previously a US-based non-executive director, has taken on the role of US commercial director with responsibility for retail marketing. Firebrick points to his experience with retail chains such as CVS and Walgreens and with wholesalers including McKesson, Cardinal Health and AmerisourceBergen. The report does not state any retailer agreements, order volumes or start dates for shelf availability.

Earlier in the quarter, on 27 July 2026, the company issued an investor update tied to the chief executive's presentations at the TechKnow investor conferences in Melbourne and Sydney.

Products and trading

Firebrick says work continued on the next product in the Nasodine range, and Nasodine Sinus Rinse launched on 21 October 2026, after the end of the quarter. The company's profile describes Nasodine Nasal Spray, containing 0.5 per cent povidone-iodine, as launched in the US, Singapore and Fiji and approved in Indonesia and the Philippines, with a throat spray added in 2026. The report contains no clinical trial or regulatory approval updates.

Receipts from customers were A$27,000 in the quarter, A$39,000 lower than in the June quarter, which the company attributes to seasonal factors. The company said annualised sales continued to grow, particularly in the United States. No dollar figure for annualised sales is given in the report.

Cash flow and costs

Cash operating payments were A$729,000, down A$110,000 on the June quarter, mainly because Research and Development spending was A$98,000 lower. The components were staff costs of A$384,000, administration and corporate costs of A$182,000, Advertising and Marketing of A$51,000, research and development of A$44,000, product Manufacturing and operating costs of A$42,000 and leased Assets of A$26,000.

The company received A$293,000 under the research and development tax incentive for FY26 Nasodine research and development costs of A$673,000, plus A$3,000 of interest. Net cash used in Operating Activities was A$398,000, and a further A$49,000 went on Equity issue transaction costs. Cash fell by A$447,000, from A$1.322 million at the start of the quarter to A$875,000 at the end. The Appendix 4C line for the net change in cash appears to show the opening balance rather than the decrease, so the decrease here is derived from the other lines. Payments to related parties, covering executive salaries and non-executive director fees, were A$285,000.

Funding position and next steps

Firebrick Pharma (ASX:FRE) has no Debt facilities in place or drawn. Using cash of A$875,000 and the quarter's operating outflow of A$398,000, it calculates an estimated runway of 2.2 quarters. Because that is above two quarters, the follow-up funding questions in the Cash Flow report were not required to be answered. The report does not describe any new Capital raising.

The company's stated focus is the US retail rollout led by Mr Moghaddam and the continuing launch of the Nasodine range, including the Sinus Rinse launched on 21 October. No dates have been set out in the report for US pharmacy availability. The report was released by Executive Chairman Dr Peter Molloy.